摘要目的:探讨沙库巴曲缬沙坦钠片联合通心络胶囊在急性心肌梗死（AMI）患者经皮冠状动脉介入（PCI）术后中的应用价值。方法:选取2021年11月至2023年10月在西安市中医医院行PCI治疗的194例AMI患者作为研究对象。通过电脑编码，将患者随机分为对照组（97例）和联合组（97例）。对照组男56例，女41例；年龄36～74（55.83±8.42）岁；PCI术后1～6（3.49±0.63）h。联合组男53例，女44例；年龄36～75（55.87±8.46）岁；PCI术后1～6（3.53±0.58）h。对照组采用常规治疗联合沙库巴曲缬沙坦钠片口服治疗，联合组在对照组基础上采用通心络胶囊口服治疗。两组均治疗8周，治疗后随访6个月。比较两组治疗前后心肌梗死溶栓试验（TIMI）血流分级、心功能［左心室收缩末期内径（LVESD）、左心室舒张末期内径（LVEDD）、左心室射血分数（LVEF）］和炎症因子水平［超敏C反应蛋白（hs-CRP）和白细胞介素（IL）-6］，随访期间主要不良心血管事件（MACE）发生情况。采用独立样本 t检验、配对 t检验、秩和检验和 χ2检验。 结果:治疗后，联合组TIMI血流分级优于对照组（ P<0.05）；联合组LVESD［（32.44±4.29）mm］、LVEDD［（40.35±4.92）mm］均低于对照组［（38.64±4.82）mm、（47.82±5.73）mm］，LVEF［（65.83±5.78）%］高于对照组［（58.36±5.36）%］（均 P<0.05）；联合组hs-CRP［（3.11±1.28）mg/L］、IL-6［（12.43±3.27）ng/L］水平均低于对照组［（6.84±1.93）mg/L、（15.68±3.94）ng/L］（均 P<0.05）。随访期间，联合组MACE总发生率［12.37%（12/97）］低于对照组［26.80%（26/97）］（ P<0.05）。 结论:沙库巴曲缬沙坦钠片与通心络胶囊联合使用可改善AMI患者PCI术后心功能和炎症因子水平，降低MACE总发生率。

abstractsObjective:To investigate the application value of Sacubitril/Valsartan sodium tablets combined with Tongxinluo capsules in patients after percutaneous coronary intervention (PCI) for acute myocardial infarction (AMI).Methods:A total of 194 AMI patients who underwent PCI at Xi'an Hospital of Traditional Chinese Medicine from November 2021 to October 2023 were selected for the study objects. They were randomly divided into a control group (97 cases) and a combined group (97 cases) using computer coding method. In the control group, there were 56 males and 41 females, aged 36-74 (55.83±8.42) years, 1-6 (3.49±0.63) h after PCI. There were 53 males and 44 females in the combined group, aged 36-75 (55.87±8.46) years, 1-6 (3.53±0.58) h after PCI . The control group was treated with Sacubitril/Valsartan sodium tablets combined with conventional treatment, while the combined group additionally received Tongxinluo capsules. After 8 weeks of treatment, they were followed up for 6 months. The blood flow grading of thrombolysis in myocardial infarction (TIMI), cardiac function [left ventricular end-systolic diameter (LVESD), left ventricular end-diastolic diameter (LVEDD), and left ventricular ejection fraction (LVEF)] and levels of inflammatory factors [hypersensitive C-reactive protein (hs-CRP) and interleukin (IL) -6] before and after treatment, and incidence of major adverse cardiovascular events (MACE) during follow-up were compared between the two groups. Independent sample t test, paired t test, rank sum test, and χ2 test were used. Results:After treatment, the TIMI blood flow grading in the combined group was better than that in the control group ( P<0.05). After treatment, the LVESD [(32.44±4.29) mm] and LVEDD [(40.35±4.92) mm] in the combined group were lower than those in the control group [(38.64±4.82) mm and (47.82±5.73) mm], and the LVEF [(65.83±5.78)%] was higher than that in the control group [(58.36±5.36)%] (all P<0.05); the levels of hs-CRP [(3.11±1.28) mg/L] and IL-6 [(12.43±3.27) ng/L] in the combined group were lower than those in the control group [(6.84±1.93) mg/L and (15.68±3.94) ng/L] (both P<0.05). During follow-up, the total incidence of MACE in the combined group [12.37% (12/97)] was lower than that in the control group [26.80% (26/97)] ( P<0.05). Conclusion:The combination of Sacubitril/Valsartan sodium tablets and Tongxinluo capsules can improve the cardiac function and the levels of inflammatory factors in AMI patients after PCI, and reduce the total incidence of MACE.